Special Issue

Influenza Virus Infections, Vaccines and Diagnosis

Message from the Guest Editors

In this Special Issue, we encourage the submission of papers—such as research articles, case reports, and reviews—focused on recent advances in the field. We particularly welcome studies that examine host—pathogen relationships and the dynamics of innate and adaptive immune responses. We are also interested in developing novel and broadly effective prophylactic or therapeutic approaches to treat influenza.

Guest Editors

Dr. Roberta Antonia Diotti Pomona Ricerca S.r.I., 10122 Torino, Italy

Dr. Isabel Pagani

IRCCS Ospedale San Raffaele, 20132 Milano, MI, Italy

Valeria Caputo

Pomona Ricerca S.r.l., 10122 Torino, Italy

Deadline for manuscript submissions

31 March 2026



an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



mdpi.com/si/239295

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

mdpi.com/journal/vaccines





an Open Access Journal by MDPI

Impact Factor 3.4 CiteScore 9.9 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).

